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Abstract
Amyloid β-protein (Aβ) self-assembly into toxic oligomers and fibrillar polymers is believed to
cause Alzheimer’s disease (AD). In the AD brain, a high percentage of Aβ contains Met-sulfoxide
at position 35, though the role this modification plays in AD is not clear. Oxidation of Met35 to
sulfoxide has been reported to decrease Aβ assembly and neurotoxicity, whereas surprisingly,
Met35 oxidation to sulfone yields similar toxicity to unoxidized Aβ. We hypothesized that the
lower toxicity of Aβ-sulfoxide might result not only from structural alteration of the C-terminal
region, but also from activation of methionine-sulfoxide reductase (Msr), an important component
of the cellular antioxidant system. Supporting this hypothesis, we found that the low toxicity of
Aβ-sulfoxide correlated with induction of Msr activity. In agreement with these observations, in
MsrA−/− mice the difference in toxicity between native Aβ and Aβ-sulfoxide was essentially
eliminated. Subsequently, we found that treatment with N-acetyl-Met-sulfoxide could induce Msr
activity and protect neuronal cells from Aβ toxicity. In addition, we measured Msr activity in a
double-transgenic mouse model of AD and found that it was increased significantly relative to
non-transgenic mice. Immunization with a novel methionine sulfoxide-rich antigen for six months
led to antibody production, decreased Msr activity, and lowered hippocampal plaque burden. The
data suggest an important neuroprotective role for the Msr system in the AD brain, which may
lead to development of new therapeutic approaches for AD.
Oxidative stress occurs in biological systems when generation of reactive oxygen species
(ROS) and reactive nitrogen species (RNS), such as hydroxyl radicals and peroxynitrite
ions, exceeds the system’s capacity to eliminate these species (1). This situation may result
from a disturbance in production and/or distribution of antioxidants or from environment-
induced elevation of ROS/RNS. Oxidative stress is a major deleterious mechanism in
Alzheimer’s disease (AD) (2), other neurodegenerative diseases (3), and normal aging (4).
In AD, oxidative damage markers, including lipid peroxidation and nitration, nucleic acid
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oxidation, and protein carbonylation are increased in vulnerable brain areas relative to age-
matched healthy individuals (5).
AD is characterized pathologically by extracellular amyloid plaques comprising
predominantly fibrillar amyloid β-protein (Aβ) and intracellular neurofibrillary tangles made
of hyperphosphorylated tau (6). Amyloid plaques are surrounded by inflammation, including
activated microglia and astrocytes, which contribute to creation and maintenance of
oxidative stress (6). Though historically amyloid plaques were thought to cause AD (7),
current evidence indicates that the pathological process leading to AD begins with synaptic
injury by neurotoxic Aβ oligomers, whereas formation of plaques and tangles are
downstream events (8). Oxidative stress is one of the earliest consequences of toxic insults
mediated by soluble Aβ oligomers (9). Mitochondria are particularly sensitive to oxidative
stress and reduced metabolic activity resulting from oxidative damage to vital mitochondrial
components has been demonstrated in AD (10). Consequently, antioxidant therapy has been
associated with reduced risk for AD (11, 12).
Aβ exists predominantly in two major forms comprising 40 (Aβ40) or 42 (Aβ42) amino acid
residues. Genetic, physiologic, and biochemical evidence indicates that Aβ42 plays a
predominant role in the pathogenesis of AD (13). A single Met residue in Aβ, Met35, is
located in the middle of the hydrophobic C-terminal region (Aβ(29–42)). Therefore, the
dramatic increase in polarity of the Met side chain that occurs upon oxidation has a profound
effect on the hydropathy of the entire region (14). Met is highly susceptible to oxidation in
vivo, particularly under conditions of oxidative stress. The sulfoxide form has been found to
comprise 10–50% of Aβ in amyloid plaques of AD brain (15–18), though it is not clear
whether its existence contributes to AD etiology or results from the highly oxidative
environment around amyloid plaques where fibrillar Aβ may be trapped for long periods.
In addition to oxidation of Met to Met-sulfoxide (Met(O)), Met can undergo a second
oxidation reaction yielding Met-sulfone (Met(O2)). Met(O2) has been found in the
antioxidant protein DJ-1 in brains from patients with AD or Parkinson’s disease (PD) (19)
and may exist in Aβ (20), though its formation requires high activation energy and
consequently Met(O2) is not commonly found in vivo. When it does happen, the in vivo
oxidation of Met to Met(O2) is considered irreversible (21). In contrast, oxidation of Met to
Met(O) is reversible and the reverse reaction is catalyzed in vivo by the methionine-
sulfoxide reductase (Msr) system, comprising peptide-methionine (S)-S-oxide reductase (EC
1.8.4.11, MsrA) and peptide-methionine (R)-S-oxide reductase (EC 1.8.4.12, MsrB), which
reduce the S and R enantiomers of the sulfoxide group, respectively, providing protection
against oxidative stress (22). Mammalian MsrA is encoded by a single gene (23) and is
found in both the cytosol and mitochondria due to alternative splicing of an N-terminal
mitochondrial signal sequence and myristoylation of the cytosolic form (24). MsrA levels
decrease with aging (25) and in AD (26). Studies in MsrA−/− mice have shown increased
vulnerability to oxidative stress (27) and oxidative pathology associated with AD (28) and
PD (29). Conversely, overexpression of MsrA in various organisms has been shown to
provide enhanced protection against oxidative stress and extend survival rate (30–32).
Several laboratories have reported lower toxicity of Aβ-Met(O) relative to WT Aβ (33). This
lower toxicity largely has been attributed to the tendency of Aβ-Met(O) to aggregate with
slower kinetics (34) and/or form smaller oligomers relative to WT Aβ (14), which correlate
with structural differences between native and oxidized Aβ in the C-terminal region (35, 36).
However, recent examination of the sulfoxide and sulfone forms of Aβ alongside the WT
form found that although Aβ-Met(O) showed reduced toxicity, as expected, the toxicity of
Aβ-Met(O2), which was used as a control, was surprisingly similar to that of WT Aβ in
assays of neuronal apoptosis, dendritic spine morphology, and Ca2+ homeostasis (37). These
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data suggested that the lower activity of Aβ-Met(O) might result not only from an altered
structure in the C-terminal region of Aβ or alteration of Aβ oligomerization, but also from
other mechanisms, possibly Msr activation, which might be unique to the sulfoxide form,
despite the similarity in the structure and calculated dipole moment between Met(O) and
Met(O2) (14, 38). Consistent with this hypothesis, a recent study has reported elevated MsrA
activity and mRNA levels in human neuroblastoma (IMR-32) cells in response to treatment
with Aβ42-Met(O) suggesting that the cells sensed the presence of Met(O) in Aβ and
upregulated MsrA to provide enhanced cellular protection (39).
To test the hypothesis that Msr activation contributes to the lower toxicity observed for Aβ-
Met(O) relative to Aβ-Met(O2) and WT Aβ, here, we compared the effect of the WT,
sulfoxide, and sulfone forms of Aβ40 and Aβ42 on the viability and Msr activity of rat
primary cortical neurons. The findings led us to explore the role of the different Msr
isoforms in the cellular response to Aβ by using the same experimental paradigm in primary
neurons from WT and MsrA−/− mice. In addition, we hypothesized that the Msr system
could be used as a target for development of therapeutic agents against Aβ-induced
oxidative stress and to test this hypothesis, we studied the possibility of inducing a
neuroprotective response by activating the Msr system, both in cell culture, using a Met(O)
derivative, and in vivo by immunization with a Met(O)-rich antigen.
Materials and Methods
Peptides synthesis
Aβ40, [Met(O)35]Aβ40, [Met(O2)35]Aβ40, Aβ42, [Met(O)35]Aβ42, and [Met(O2)35]Aβ42
were synthesized by incorporating FMOC-Met(O) or FMOC-Met(O2) (EMD Biosciences,
San Diego, CA) in position 35 where appropriate, purified, and characterized in the UCLA
Biopolymers Laboratory. Quantitative amino acid analysis and mass spectrometry were used
to characterize the expected compositions and molecular weights, respectively, for each
peptide. N-acetyl-D,L-Met(O) (Ac-Met(O)) was purchased from Sigma (St. Louis, MO).
Preparation of peptide solutions
Purified peptides were stored as lyophilized powders at −20°C. Before use, peptides were
treated with 1,1,1,3,3,3-hexafluoroisopropanol (HFIP, TCI America, Portland, OR) to
disassemble pre-formed aggregates and stored as dry films at −20°C as described previously
(40). Immediately before use, peptide films were dissolved in 60 mM NaOH at 10% of the
desired volume, diluted with cell-culture media followed by 1 min sonication and added to
the cells at a final concentration of 10 μM unless otherwise stated. The final NaOH
concentration was ≤6 mM and the pH change of the media was negligible.
Animals
All experiments were compliant with the National Research Council Guide for the Care and
Use of Laboratory Animals and were approved by the respective Animal Research Councils
and the Ethics Committees of UCLA or KU. Pregnant (E18) Sprague-Dawley rats and
C57Bl/6 mice were purchased from Charles River Laboratories (Wilmington, MA). Double-
transgenic (2×Tg) mice overexpressing familial-AD linked mutant forms of amyloid β-
protein precursor (APP) and presenilin 1 (B6C3 Tg(APPswe, PSEN1dE9)85Dbo/J) and
control, non-Tg mice on the same genetic background were purchased from Jackson
Laboratories (Bar Harbor, ME). MsrA−/− mice were bred and maintained in house.
Cell culture
Primary cortical or hippocampal neurons were prepared as described previously (37).
Briefly, E18 pregnant rats or mice were euthanized with CO2 and the pups were collected
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immediately. The brains were dissected in chilled Leibovitz’s L-15 medium (ATCC,
Manassas, VA) in the presence of 1 μg/ml penicillin/streptomycin (Invitrogen, Carlsbad,
CA) and the cells were suspended in Dulbecco’s Modified Eagle’s Medium (DMEM,
obtained from ATCC) containing 10% heat-inactivated fetal bovine serum (ATCC) and
penicillin/streptomycin (1 μg/ml), and plated in poly D-lysine (0.1 mg/ml, Sigma)-coated
96-well COSTAR plates (Corning, Lowell, MA) at a density of 3×105 cells/ml. The cultures
were maintained for 6 d before treatment with peptides. Twenty-four hours after plating, the
medium was replaced with fresh medium supplemented with 5 μM cytosine β-D-
arabinofuranoside (Sigma) to inhibit the proliferation of glial cells. PC-12 cells were
cultured and differentiated with 50 ng/ml nerve growth factor (NGF) 24 h prior to treatment
with peptides as described previously (41).
MTT reduction assay
Cells were treated with freshly prepared Aβ analogues for 48 h. Cell viability was measured
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell-
metabolism assay, as described previously (41). Briefly, following treatment, 15 μl of MTT
were added to each well and incubated for 4 h at 37°C. Then, stop solution was added and
kept overnight at 25°C. The optical density was measured using a Synergy plate reader (Bio-
TEK instruments, Winooski, VT). The cell viability results of three independent
experiments (6 wells per data point) were normalized to the medium control group and
expressed as mean ± SEM. Neuroprotection experiments were performed in a similar
manner using 10 μM Aβ42 in the absence or presence of Ac-Met(O).
Lactate dehydrogenase (LDH) release assay
Neurons were incubated with Aβ analogues for 48 h and cell death was assayed by
measuring the release of LDH as described previously (42). Data from 6 independent
experiments (6 wells per data point) were normalized to medium control and expressed as
mean ± SEM.
Measurement of Msr activity
Total Msr activity was measured in rat or mouse primary cortical neurons, or differentiated
PC-12 cells, as described previously (32). Briefly, the cells were treated with 10 μM of each
peptide for 24 h. Similarly, in protection experiments, differentiated PC-12 cells were
treated for 24 h with Ac-Met(O) in the absence or presence of 10 μM Aβ42. Following the
incubation, the culture medium was removed and the cells were washed with PBS, pH 7.4.
Then, the cells were lysed in PBS by 1-min sonication in an ice-water bath in the presence
of a protease-inhibitor cocktail (Sigma). Insoluble material was removed by centrifugation at
14,000 g for 10 min at 4°C and supernates were stored at −80°C until use. Protein
concentration was determined using a Bradford protein assay kit (Bio-Rad, Hercules, CA)
and used to normalize the volume used for determination of Msr activity. Supernates (100
μg protein) were incubated with 100 μl of 50 mM Tris-HCl, pH 7.5, containing 20 mM DTT
and 200 μM dabsyl-Met(O) for 1 h at 37°C. Then, the reaction was stopped by adding an
equal volume of acetonitrile and the mixture was analyzed by an HPLC system equipped
with a C18 column using a gradient starting at 100% 0.14 M sodium acetate, pH 6.0, and
increasing the percentage of acetonitrile to 70% over 30 min. The dabsyl-Met(O) and
dabsyl-Met peaks were detected at 436 nm. The basal specific activity measured in control
cells treated with medium alone was the following (in pmoles dabsyl-Met formed/min/mg
protein): primary WT rat neurons − 240, primary WT mouse neurons − 150, primary
MsrA−/− neurons − 80, PC-12 cells − 200. The specific activity in Aβ-treated cells was
normalized to the medium-treated cells and expressed as % change of Msr activity (mean ±
SEM).
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Immunization of 2×Tg mice
2×Tg mice (43) were immunized with oxidized zea mays Met-rich protein (DZS18) (44)
with complete Freund’s adjuvant for the first injection, followed by oxidized DZS18 with
incomplete Freund’s adjuvant every 2 weeks for 6 months beginning at 3 months of age.
2×Tg mice injected with adjuvant only, unimmunized mice, and non-Tg mice of the same
genetic background served as control groups (5 mice per group). At the end of the
immunization period, the mice were euthanized, their brains were collected, frozen, and
sectioned, and brain sections were analyzed for aggregated Aβ deposition using thioflavin S
(ThS) staining. Additionally, Msr specific activity in brain were measured using the HPLC
assay described above for cultures cells.
Detection of serum immunoglobulins by Western blot
Sera were collected from 2×Tg mice immunized with oxidized DZS18 or adjuvant alone, or
unimmunized mice (n = 5 per group). Oxidized, recombinant DZS18 was loaded onto 4–
20% gradient gels (Pierce, Rockford, IL, 5 μg per lane) and subjected to SDS-PAGE. The
protein was transferred to nitrocellulose membranes and each lane was probed with serum
from one mouse (1:500 dilution), followed by HRP-conjugated goat-anti-mouse IgG (1:5000
dilution, Invitrogen, Carlsbad, CA). The bands were visualized using ECL.
ThS staining
Coronal, 45-μm brain sections were prepared using a Microm HM 360 microtome (Harlow
Scientific, Arlington, VA), immersed for 3 min each in 95% and 70% ethanol followed by
5-min incubation in 1% ThS in deionized water (Sigma) and quick rinses in 80% ethanol
and deionized water. The sections then were dehydrated by consecutive 1 min incubations in
70%, 95%, and 100% ethanol and immersed in xylene for 3 min prior to aqueous mounting
in glycerin jelly. ThS fluorescence was imaged and quantified using a fluorescence
microscope (GE Healthcare, Waukesha, WI) with a high-content imaging system (GE
Healthcare). The number of ThS-positive plaques per equivalent hippocampal area (plaque
burden) was measured and quantified using ImageJ.
Data analysis
Data are expressed as mean ± SEM. They were analyzed by one-way analysis of variance
(ANOVA) with post hoc Tukey’s test.
Results
Effect of WT and oxidized Aβ on neuronal viability
To investigate the neurotoxic effects of native and oxidized Aβ variants on cellular viability
and survival, we used two different toxicity assays, MTT reduction and LDH release, in rat
primary cortical or hippocampal neurons (Fig. 1). We used both assays because methods for
determining Aβ toxicity are not consistent across the AD field. Each of these assays
addresses a different aspect of cell toxicity: The MTT assay measures mitochondrial activity
of viable cells, whereas the LDH assay detects membrane integrity as a direct measurement
of cell death.
Compared to cells treated with medium containing the same concentration of NaOH (used
for initial peptide solubilization) but no Aβ, Aβ40 caused a decrease of 27±1% and 17±2%
in cortical neuron viability, and 18±1% and 14±2% in hippocampal neuron viability in the
MTT (Fig. 1A, C) and LDH (Fig. 1B, D) assays, respectively. Aβ40-Met(O) was 5–10%
less toxic than WT Aβ40 whereas Aβ40-Met(O2) had similar toxicity to WT Aβ40. Overall,
the differences observed among the Aβ40 analogues were not statistically significant. We
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also did not find significant differences between the response of cortical (Fig. 1A, B) and
hippocampal (Fig. 1C, D) neurons to Aβ40 analogues.
Under the same conditions, Aβ42 showed 41±3% and 25±2% decrease in cortical neuron
viability and 43±2% and 27±3% decrease in hippocampal neuron viability in the MTT (Fig.
1A, C) and LDH (Fig. 1B, D) assays, respectively. Similar to previously described data (37),
Aβ42-Met(O) was significantly less toxic, causing 31±1% and 17±1% decrease in cortical
neuron viability and 34±1% and 16±2% decrease in hippocampal neuron viability,
respectively (Fig. 1). These levels of toxicity were similar to those of Aβ40 analogues in the
LDH assay (Fig. 1A, B), whereas in the MTT assay, Aβ42-Met(O) showed toxicity that was
intermediate between those induced by Aβ40 and Aβ42 (Fig. 1C, D). Aβ42-Met(O2) showed
similar toxicity to WT Aβ42 in all cases, causing 40±2% and 24±3% decrease in cortical
neuron viability and 43±2% and 23±3% decrease in hippocampal viability in the MTT and
LDH assays, respectively (Fig. 1). Thus, as reported previously (37), both assays showed
that despite the similar increase in dipole moment upon oxidation of Met35 to Met(O) or
Met(O2) (14, 38), and despite the change in the oligomer size distribution of the sulfoxide
and sulfone forms of Aβ42 relative to WT Aβ42 (14), only Aβ42-Met(O) was less toxic to
cells than WT Aβ42.
Msr response to WT and oxidized Aβ
The toxicity of the six Aβ alloforms correlated with aggregation kinetics (37) but not with
oligomer size distribution or polarity of the C-terminus (14). To test whether the Msr system
might be involved, we measured cellular levels of Msr activity following treatment with
each Aβ analogue. Because relatively high toxicity levels were observed following a 48-h
incubation with Aβ42 or Aβ42-Met(O2) (Fig. 1), we used a 24-h incubation in these
experiments.
We found that WT Aβ40 and Aβ42 caused a small (6±6% and 3±5%, respectively),
insignificant increase in Msr activity relative to untreated cells (Fig. 2A), whereas Aβ40-
Met(O) and Aβ42-Met(O) increased total Msr activity significantly (25±6% and 27±11%,
respectively) relative to untreated cells (Fig. 2A). In contrast, following treatment with
Aβ40-Met(O2) or Aβ42-Met(O2), we observed a moderate, non-significant decrease of
3±4% and 10±4%, respectively, in Msr activity compared to control cells (Fig. 2A). Dose–
response analysis of the effect of Aβ40-Met(O) or Aβ42-Met(O) on Msr activity showed
that in both cases, the measured total Msr activity increased between 1–10 μM of Aβ and
decreased at 30 μM Aβ, likely due to high levels of apoptosis at the highest concentration
(Fig. 2B). Differences in Msr activity levels by Aβ40-Met(O) or Aβ42-Met(O) between
Figs. 2A and B reflect experimental variability. These findings support the hypothesis that
neurons sense the presence of the sulfoxide group in Aβ and respond by activating the Msr
system as self-protection against oxidative stress.
Examination of Aβ analogues in MsrA−/− neurons
To gain insight into the relative contribution of Msr isozymes to the response to Aβ-Met(O),
we measured neurotoxicity and Msr activation in primary cortical neurons from MsrA−/−
mice and compared the data to neurons from WT mice. In these experiments, we used only
Aβ42 analogues because the differences observed among the different Aβ forms were
similar in trend, yet greater in magnitude for Aβ42 than for Aβ40. We predicted that if MsrA
were the main isozyme responsible for the lower observed toxicity of Aβ42-Met(O) relative
to WT Aβ42 and Aβ42-Met(O2), the difference among the three Aβ analogues would
disappear when tested in MsrA−/− neurons, i.e., Aβ42-Met(O) would show the same level of
toxicity as the other two analogues. In contrast, if MsrB compensated for the absence of
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MsrA, we expected that each Aβ42 alloform would behave similarly, regardless of whether
the neurons were WT or MsrA−/−.
In WT neurons, Aβ42-Met(O) was significantly less toxic than WT Aβ42 or Aβ42-Met(O2)
in the MTT assay (Fig. 3A). In contrast, in neurons from MsrA−/− mice, Aβ42, Aβ42-
Met(O), and Aβ42-Met(O2) caused a similar decrease in viability (Fig. 3A) and the
differences among the three alloforms were insignificant. Thus, the absence of MsrA
appeared to render the neurons more susceptible to the toxic effect of all three alloforms
suggesting that MsrA was the predominant isozyme protecting the neurons from Aβ42-
Met(O) toxicity. Similar results were obtained in the LDH assay. In neurons from WT mice,
Aβ42-Met(O) caused significantly less cell death relative to WT Aβ42 or Aβ42-Met(O2). In
contrast, in MsrA−/− neurons, Aβ42, Aβ42-Met(O), or Met(O2) induced similar levels of cell
death, respectively and the differences were insignificant.
Measurement of Msr activity showed that the specific Msr activity in MsrA−/− neurons (80
pmol dabsyl-Met/min/mg protein) was approximately half that of WT neurons (150 pmol
dabsyl-Met/min/mg protein), consistent with the absence of MsrA. The pattern of response
of the MsrA−/− neurons to the three Aβ42 analogues was similar to that of WT neurons
though the differences, which reflect MsrB only, did not reach statistical significance. These
results suggest that in the absence of MsrA, neurons still sense the presence of the sulfoxide
group in Aβ42-Met(O) and respond by elevation of MsrB activity, but this response
provides little neuroprotection compared to WT neurons.
Induction of a protective Msr response by a Met(O) derivative in cell culture
Based on the findings described above, we asked next whether the Msr system could be
induced to protect neurons against Aβ42 toxicity. Our first approach was an attempt to
protect cultured cells by application of Ac-Met(O). Because of the exploratory nature of
these experiments, we used here differentiated PC-12 cells rather than primary neurons.
Evaluation of cell viability using the MTT (Fig. 4A) and LDH (Fig. 4B) assays showed that
1 mM Ac-Met(O) rescued Aβ42-induced toxicity to the levels of untreated cells. Lower
concentrations of Ac-Met(O) showed partial rescue (data not shown). The rescue by 1 mM
Ac-Met(O) correlated with a significant, 44±4% increase in Msr activity (Fig. 4C). The data
suggest that induction of an Msr response by exposure of cells to Ac-Met(O) or derivatives
thereof is a viable neuroprotective strategy against Aβ42-induced toxicity.
Induction of a protective Msr response by immunization with a Met(O)-rich antigen in vivo
To test whether induction of the Msr system could be beneficial in vivo, we immunized
2×Tg mice bearing FAD-linked mutant app and psen1 genes (45) with a Met(O)-rich
antigen, which recently has been used to create a unique anti-Met(O) antibody (46). This
antigen is an oxidized form of recombinant zea mays methionine-rich protein (DZS18). The
anti-Met(O) antibody was developed to recognize Met(O) in any protein. It was shown to
detect increased Met(O) levels in plasma from aged WT mice or MsrA−/− mice compared
with young WT mice, from patients with AD compared with healthy age-matched
individuals (46), and in symptomatic and pre-symptomatic persons carrying familial AD-
linked mutations in app or psen1 compared to non-carriers from the same kindreds (47).
Here, we used oxidized DZS18 to immunize 2×Tg AD mice. These mice produce high
levels of Aβ, particularly Aβ42, in their brain and display Aβ deposition in amyloid plaques
as early as 4 months of age with progression up to 12 months of age (48). We hypothesized
that immunization with the Met(O)-rich antigen initially would induce higher Msr activity,
but over time would produce an immune response that might lead to decreased levels of
Met(O) in proteins and subsequent decrease in Msr activity. Because a large portion of Aβ
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Met35 in amyloid plaques is oxidized to sulfoxide (15), we hypothesized also that
immunization with oxidized DZS18 might help clear the amyloid burden in the brains of the
mice.
Mice were immunized every 2 weeks for 6 months beginning at 3 months of age. At the end
of the immunization period, their serum was analyzed for Msr activity and production of
anti-Met(O) antibodies, and brain sections were stained with ThS for visualization of
amyloid plaques. As shown in Fig. 5, Msr activity in the brain of unimmunized 2×Tg mice
was 40±15% higher than in WT mice. Immunization of the 2×Tg mice with oxidized
DZS18, but not with adjuvant alone, caused a significant decrease in brain Msr activity by
26±10% (Fig. 5A), consistent with our prediction. Analysis of mouse serum showed
immunoglobulins reactive towards oxidized DZS18 in immunized mice, but not in mice
receiving adjuvant alone or unimmunized mice (Fig. 5B). ThS staining showed abundant
plaques in unimmunized mice (Fig. 5C). Immunization with oxidized DZS18 caused a
significant, 28±8% reduction in plaque burden in the hippocampus of the immunized mice
relative to the control groups (Fig. 5D–F). The data suggest that immunization with a
Met(O)-rich, non-Aβ antigen can produce amyloid plaque clearance in the brain of 2×Tg
AD mice, presumably by removing the oxidized form of Aβ or other plaque-associated
proteins, and that production of an immune response against Met(O) may alleviate in part
the oxidative stress that causes increased Msr activity in these mice.
Discussion
Met35 is the primary target site for oxidants in Aβ (33). Formation of methionyl radicals and
participation of Met in Fenton chemistry in the presence of transition metal ions leading to
production of ROS have been hypothesized to play an important role in Aβ-induced toxicity.
Once Met gets oxidized to sulfoxide or sulfone, its tendency to participate in further
oxidation reactions or form radicals decreases substantially. Thus, if participation of Met35
in these reactions were important for Aβ-induced toxicity, Aβ would be predicted to become
less toxic upon oxidation. This hypothesis has been supported by a number of studies
comparing the toxicity of WT Aβ42 to Aβ42-Met(O) (33). Surprisingly, however, even
though Aβ-Met(O2) is less likely than Aβ-Met(O) to form radicals or participate in Fenton
chemistry, it induces the same levels of neurotoxicity and synaptotoxicity as WT Aβ (Fig. 1,
(37, 49)). These results have led us to hypothesize that factors other than the effect of
oxidation on Aβ conformation and assembly, for example, activation of the Msr system,
contributed to the observed differences between the toxicity levels of WT Aβ and Aβ-
Met(O).
The observation of a significant increase in Msr activity in response to Aβ-Met(O), but not
WT Aβ or Aβ-Met(O2), in WT rat (Fig. 2) and mouse (Fig. 3) primary neurons suggests that
Msr protects neurons from Aβ-Met(O) toxicity. Supporting our findings, similar
observations have been made recently by Misiti et al. in IMR-32 cells, who reported also an
increase in MsrA transcription upon treatment with Aβ-Met(O) (39). Interestingly, although
Msr reduces the less toxic Aβ-Met(O) to the more toxic WT Aβ, the overall result is
significantly lower toxicity (Fig. 1). This suggests that Msr-mediated reduction of Met(O) to
Met in cellular proteins other than Aβ overrides the direct toxicity caused by Aβ itself
through other mechanisms, emphasizing the role of oxidative damage in the array of toxic
mechanisms induced by Aβ.
In both the MTT and LDH assays (Fig. 3A,B) the absence of MsrA resulted in elimination
of the significant decrease in toxicity induced by Aβ42-Met(O) relative to WT Aβ42 or
Aβ42-Met(O2). These results suggested that the main neuroprotective activity was provided
by MsrA rather than MsrB. Indeed, the overall specific Msr activity found in MsrA−/− cells,
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which must be provided by MsrB, was about half that in WT neurons. Previously, ablation
of the mouse MsrA gene was shown to lower the expression level of MsrB1 (50). Our data
suggest that in response to treatment with Aβ42-Met(O), the neurons still upregulate MsrB
(Fig. 3C), but this provides only partial protection and the observed toxicity is higher in the
MsrA−/− mice than in WT mice. The putative partial protection provided by MsrB in
MsrA−/− cells appeared to be higher in the LDH assay (Fig. 3B) than in the MTT assay (Fig.
3A). This observation suggests that in mitochondria, where MsrA is the main isoform (51),
the capability of MsrB to mitigate oxidative stress is lower than in the cytosol. The
mitochondrial MsrB isoforms, MsrB2 and MsrB3B are minor isoforms (52) and presumably
have a limited capability to compensate for the absence of MsrA, whereas the cytosolic
MsrB1 may offers somewhat higher levels of compensation as reflected in the LDH assay.
Overexpression of MsrA has been shown to be protective against oxidative stress in multiple
systems (22), whereas MsrA ablation enhanced oxidative posttranslational modifications
and resulted in accumulation of damaged proteins, similar to findings in neurodegenerative
diseases (53). These studies and the data presented here suggest that activating the Msr
system using sulfoxide-containing compounds may serve as a novel route for development
of therapeutic agents against AD and other neurodegenerative diseases, and for general
reduction of aging-related oxidative stress. Here, we used Ac-Met(O) to test this hypothesis
and found that this simple amino-acid derivative induced elevated Msr activity and protected
differentiated PC-12 cells against Aβ42-induced toxicity (Fig. 4). These results provide
proof of principle for activation of Msr using non-toxic Met(O) derivatives and suggest that
exploration of derivatives with higher activity and desirable pharmacokinetic characteristics
may yield novel drug candidates for conditions in which oxidative stress is a major
deleterious mechanism.
The experiments using Ac-Met(O) did not distinguish between MsrA and MsrB because the
compound we used comprised all four diastereomers. MTT experiments using Ac-L-Met(O)
or Ac-D-Met(O) showed that both isomers significantly protected differentiated PC-12 cells
against Aβ-induced toxicity to a similar extent (data not shown). Experiments using the R-
or S- enantiomers of the sulfoxide group will be pursued in the future.
Immunization has been explored widely as a therapeutic approach for AD, with mixed
results (54). Immunization with Aβ-derived antigens or passive immunization with anti-Aβ
antibodies has been shown to reduce Aβ burden in patients with AD and in animal models
(55). However, neuroinflammation, induction of vasogenic edema and/or
microhemorrhages, and other adverse effects have raised concerns regarding the safety of
this approach and multiple attempts have been made to develop safer immunization
strategies (56). One such strategy is to use surrogate antigens based on Aβ-unrelated protein
sequences that may promote Aβ clearance without causing the problems mentioned above
(57). Here we used a similar approach with a unique antigen – oxidized maize Met-rich
protein, which has no sequence similarity with Aβ, and observed a significant reduction of
plaque burden in the 2×Tg mice (Fig. 5C–F). These data suggest that anti-Met(O)
antibodies, similar to the one reported previously (58) were produced in the mice (Fig. 5B)
and contributed to the observed clearance of deposited Aβ via binding to Aβ-Met(O). This
offers an advantage relative to antibodies that recognize Aβ itself because only an aberrant
form of Aβ, the one containing Met(O), is targeted.
The immunization likely reduced the overall brain oxidative stress using several
mechanisms: First, by reducing the number of amyloid plaques, the inflammatory processes
surrounding the plaques were relieved. A cellular immune response (e.g., activation of
microglia) also might have participated in plaque clearance, though exploration this aspect
of the immune response was beyond the scope of the current work. Second, the antibodies
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might have promoted clearance of other oxidized (Met(O)-containing) proteins resulting in
lower overall cellular oxidative damage. Third, because oxidative damage is known to
upregulate Aβ production (59), the decrease in oxidative stress signals might have lowered
Aβ production and further facilitated reduction in Aβ burden.
Msr activity has been shown to decline in post mortem AD brain (26), yet to increase in cell
culture in response to Aβ. Our study presents for the first time evidence showing that Msr
levels are elevated in a mouse model of AD at an age in which abundant plaque deposition is
observed (Fig. 5). These findings could reflect simply a difference between mice and
humans. However, if mouse models of AD represent relatively early stages of the disease,
our findings suggest that in early AD, Msr activation is one way by which the brain attempts
to mitigate oxidative stress, yet this attempt fails in late stages. Testing this hypothesis in
human studies will validate the Msr system as a new therapeutic target and may lead to
development of novel treatments for AD that would utilize natural brain defense
mechanisms. Such treatments may have a broad impact because oxidative stress is a
common deleterious mechanism in many degenerative diseases and in normal aging.
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Figure 1. Comparison of neurotoxic effects of native and oxidized Aβ analogues
Rat primary cortical (A, B) or hippocampal (C, D) neurons were cultured for 6 d and then
treated with Aβ analogues. Cell viability was measured using the MTT reduction (A, C) or
LDH release (B, D) assays following treatment with 10 μM of each Aβ analogue for 48 h as
described previously (37). *p < 0.05; **p < 0.01.
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Figure 2. Effect of native and oxidized Aβ on Msr activity
Rat primary cortical neurons were grown for 6 d on poly-D-lysine-coated, 60-mm Petri
plates. A) Cells were incubated in the presence or absence of 10 μM of each Aβ analogue for
24 h at 37°C. The cells were lysed in PBS, pH 7.4, centrifuged, and supernates were used to
determine total specific Msr activity by HPLC using dabsyl-Met(O) as described previously
(60). The results were normalized to untreated cells (240 pmol dabsyl-Met/min/mg protein
defined as 100% specific Msr activity). The data are an average of 10–15 independent
experiments. B) Cells were treated with Aβ40-sulfoxide or Aβ42-sulfoxide at the indicated
concentrations and total specific Msr activity was determined as described above. The data
are an average of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3. Response of MSRA−/− and WT mouse primary cortical neurons to native and oxidized
Aβ42
Primary MsrA−/− or WT mouse cortical neurons were treated with 10 μM of each Aβ
analogues for 48h. A) Assessment of cell viability using the MTT assay. B) Assessment of
cell death using the LDH assay. C) Measurement of specific Msr activity by HPLC using
dabsyl-Met(O) as substrate. The results were normalized to untreated WT cells (150 pmol
dabsyl-Met/min/mg protein defined as 100% specific Msr activity). The data are an average
of 5–10 independent experiments. **p < 0.01, ***p < 0.001, NS – non-significant.
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Figure 4. Ac-Met(O) increases Msr activity in differentiated PC-12 cells and protects the cells
from Aβ42-induced toxicity
Differentiated PC-12 cells were treated for 24 h with 1 mM Ac-Met(O), 10 μM Aβ42, or 10
μM Aβ42 + 1 mM Ac-Met(O). A) Assessment of cell viability using the MTT assay. B)
Assessment of cell death using the LDH assay. C) Measurement of specific Msr activity by
HPLC. The results were normalized to untreated cells (200 pmol dabsyl-Met/min/mg protein
defined as 100% specific Msr activity). The data are an average of 10 independent
experiments. *p < 0.05, **p < 0.01.
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Figure 5. Immunization of 2×Tg mice with oxidized Met-rich protein reduces Msr activity and
brain Aβ burden
Mice were immunized for 6-months with oxidized Met-rich protein (DSZ18(ox)) or
adjuvant alone. Non-Tg mice served as a negative control and unimmunized mice as a
positive control. N = 5 mice per group. A) Measurement of specific Msr activity in mouse
brain. ***p < 0.001. NS – non-significant. B) Westren blot analysis for detection of anti-
Met(O) antibodies in sera of 2×Tg mice immunized with DZS18(ox), mice immunized with
adjuvant alone, or unimmunized mice. The smear between 45–60 kDa in the 2×Tg +
DZS18(ox) lane is an artifact that was not observed in other blots. C–E) Fluorescence
microscopy images of hippocampal brain slices stained with Thioflavin S: C) Unimmunized
mice. D) Mice immunized with DZS18(ox). E) Mice immunized with adjuvant alone. F) %
Plaque burden was quantified by calculating the total ThS-stained area divided by the total
hippocampal area measured and normalized to unimmunized mice using ImageJ (n = 5 mice
per condition, *p < 0.05).
Moskovitz et al. Page 19
Biochemistry. Author manuscript; available in PMC 2012 December 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
